Johnson & Johnson beats Q3 earnings estimates with Tremfya driving sales despite Middle East headwinds
Johnson & Johnson reported a higher-than-expected profit on Tuesday, October 13, 2026. Strong sales of immune disease treatment Tremfya drove the beat, while geopolitical issues including the Middle East conflict weighed on its medical devices business.
11
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Globe and Mail
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Globe and Mail
J&J beats earnings estimates, plans orthopedics spinoff by mid-2027
earnings beat plus spinoff announcement · positive
Reuters
J&J beats earnings estimates; Middle East conflict weighs on medical device sales
earnings beat with geopolitical headwind emphasis · neutral
First to report
- Reutersfirst
- Globe and Mail+7.6 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
Headlines that changed · the same article, re-listed with a new headline
Globe and Mail · 2026-10-13 13:35 UTC
J&J beats earnings estimates; Middle East conflict weighs on medical device sales
The split, in one line
Both outlets report the same earnings beat and Tremfya driver; Globe and Mail adds plans for an orthopedics spinoff by mid-2027 as a headline fact, while Reuters focuses solely on Middle East conflict weighing on medical device sales.
How each outlet covered it
No left-right split here
Coverage clusters in the center and international press. Here is each take as it stands.
Center & international coverage
“J&J beats earnings estimates, plans orthopedics spinoff by mid-2027”
“J&J beats earnings estimates; Middle East conflict weighs on medical device sales”
4 tracked claims across 2 outlets
Fact ledger
All4Claimed1Corroborated3
1/2
Claimed
J&J plans an orthopedics spinoff by mid-2027
Corroborated
Disputed
3 more tracked claimsSign up free to see the full ledger